NSAIDs: risk of thrombotic events but positive benefit-risk balance

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2006年 / 1125卷 / 1期

关键词：

Ibuprofen; Medicinal Product; Product Information; Thrombotic Event; Human Medicine;

D O I：

10.2165/00128415-200611250-00003

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] Positive benefit-risk balance continues for glitazones – EMEA
Reactions Weekly, 2007, 1175 (1) : 2 - 2
[2] Positive benefit-risk balance for orlistat, finds EMA
Reactions Weekly, 2012, 1390 (1) : 2 - 2
[3] PhVWP confirms reboxetine's positive benefit-risk balance
Reactions Weekly, 2011, 1370 (1) : 2 - 2
[4] The benefit-risk balance of topical formulations of ketoprofen remains positive,
Reactions Weekly, 2010, 1312 (1) : 7 - 7
[5] ASPECTS ON THE BENEFIT-RISK BALANCE OF FELODIPINE IN HYPERTENSION
ELMFELDT, D
WESTERLING, S
DRUGS, 1987, 34 : 132 - 135
[6] EMA reviews benefit-risk balance of domperidone
Reactions Weekly, 2013, 1448 (1) : 4 - 4
[7] Rofecoxib: risk of thrombotic events similar to other NSAIDs
Reactions Weekly, 2002, 892 (1) : 4 - 4
[8] Levothyroxine Alapis: risk of med errors tips benefit-risk balance
Reactions Weekly, 2012, 1426 (1) : 4 - 4
[9] The EMA's CHMP concludes that the benefit-risk balance for MabThera [rituximab] remains positive,
Reactions Weekly, 2012, 1404 (1) : 3 - 3
[10] The EMA confirms that Revlimid's [lenalidomide's] benefit-risk balance remains positive,
Reactions Weekly, 2011, 1371 (1) : 3 - 3

← 1 2 3 4 5 →